These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 32060676)

  • 1. Towards the understanding of the activity of G9a inhibitors: an activity landscape and molecular modeling approach.
    López-López E; Rabal O; Oyarzabal J; Medina-Franco JL
    J Comput Aided Mol Des; 2020 Jun; 34(6):659-669. PubMed ID: 32060676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity Landscape and Molecular Modeling to Explore the SAR of Dual Epigenetic Inhibitors: A Focus on G9a and DNMT1.
    López-López E; Prieto-Martínez FD; Medina-Franco JL
    Molecules; 2018 Dec; 23(12):. PubMed ID: 30544967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protein lysine methyltransferase G9a inhibitors: design, synthesis, and structure activity relationships of 2,4-diamino-7-aminoalkoxy-quinazolines.
    Liu F; Chen X; Allali-Hassani A; Quinn AM; Wigle TJ; Wasney GA; Dong A; Senisterra G; Chau I; Siarheyeva A; Norris JL; Kireev DB; Jadhav A; Herold JM; Janzen WP; Arrowsmith CH; Frye SV; Brown PJ; Simeonov A; Vedadi M; Jin J
    J Med Chem; 2010 Aug; 53(15):5844-57. PubMed ID: 20614940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of novel quinoline inhibitor for EHMT2/G9a through virtual screening.
    Charles MRC; Mahesh A; Lin SY; Hsieh HP; Dhayalan A; Coumar MS
    Biochimie; 2020 Jan; 168():220-230. PubMed ID: 31756401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of novel histone lysine methyltransferase G9a/GLP (EHMT2/1) inhibitors: Design, synthesis, and structure-activity relationships of 2,4-diamino-6-methylpyrimidines.
    Katayama K; Ishii K; Tsuda E; Yotsumoto K; Hiramoto K; Suzuki M; Yasumatsu I; Igarashi W; Torihata M; Ishiyama T; Katagiri T
    Bioorg Med Chem Lett; 2020 Oct; 30(20):127475. PubMed ID: 32781218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel SAR for quinazoline inhibitors of EHMT1 and EHMT2.
    Leenders R; Zijlmans R; van Bree B; van de Sande M; Trivarelli F; Damen E; Wegert A; Müller D; Ehlert JE; Feger D; Heidemann-Dinger C; Kubbutat M; Schächtele C; Lenstra DC; Mecinović J; Müller G
    Bioorg Med Chem Lett; 2019 Sep; 29(17):2516-2524. PubMed ID: 31350126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of a 2,4-diamino-7-aminoalkoxyquinazoline as a potent and selective inhibitor of histone lysine methyltransferase G9a.
    Liu F; Chen X; Allali-Hassani A; Quinn AM; Wasney GA; Dong A; Barsyte D; Kozieradzki I; Senisterra G; Chau I; Siarheyeva A; Kireev DB; Jadhav A; Herold JM; Frye SV; Arrowsmith CH; Brown PJ; Simeonov A; Vedadi M; Jin J
    J Med Chem; 2009 Dec; 52(24):7950-3. PubMed ID: 19891491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II).
    Lenstra DC; Al Temimi AHK; Mecinović J
    Bioorg Med Chem Lett; 2018 Apr; 28(7):1234-1238. PubMed ID: 29519735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insights for the design of protein lysine methyltransferase G9a inhibitors.
    Charles MRC; Dhayalan A; Hsieh HP; Coumar MS
    Future Med Chem; 2019 May; 11(9):993-1014. PubMed ID: 31141392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The discovery of novel histone lysine methyltransferase G9a inhibitors (part 1): molecular design based on a series of substituted 2,4-diamino-7- aminoalkoxyquinazoline by molecular-docking-guided 3D quantitative structure-activity relationship studies.
    Feng T; Wang H; Zhang X; Sun H; You Q
    Med Chem; 2014 Jun; 10(4):426-40. PubMed ID: 24151879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delineating the active site architecture of G9a lysine methyltransferase through substrate and inhibitor binding mode analysis: a molecular dynamics study.
    Ramya Chandar Charles M; Hsieh HP; Selvaraj Coumar M
    J Biomol Struct Dyn; 2019 Jul; 37(10):2581-2592. PubMed ID: 30047835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Properly substituted analogues of BIX-01294 lose inhibition of G9a histone methyltransferase and gain selective anti-DNA methyltransferase 3A activity.
    Rotili D; Tarantino D; Marrocco B; Gros C; Masson V; Poughon V; Ausseil F; Chang Y; Labella D; Cosconati S; Di Maro S; Novellino E; Schnekenburger M; Grandjenette C; Bouvy C; Diederich M; Cheng X; Arimondo PB; Mai A
    PLoS One; 2014; 9(5):e96941. PubMed ID: 24810902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-activity relationship studies of G9a-like protein (GLP) inhibitors.
    Xiong Y; Li F; Babault N; Wu H; Dong A; Zeng H; Chen X; Arrowsmith CH; Brown PJ; Liu J; Vedadi M; Jin J
    Bioorg Med Chem; 2017 Aug; 25(16):4414-4423. PubMed ID: 28662962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. G9a - An Appealing Antineoplastic Target.
    Chen WL; Sun HP; Li DD; Wang ZH; You QD; Guo XK
    Curr Cancer Drug Targets; 2017; 17(6):555-568. PubMed ID: 27174055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of novel small molecule inhibitors of lysine methyltransferase G9a and their mechanism in leukemia cell lines.
    Kondengaden SM; Luo LF; Huang K; Zhu M; Zang L; Bataba E; Wang R; Luo C; Wang B; Li KK; Wang PG
    Eur J Med Chem; 2016 Oct; 122():382-393. PubMed ID: 27393948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of Reversible DNA Methyltransferase and Lysine Methyltransferase G9a Inhibitors with Antitumoral in Vivo Efficacy.
    Rabal O; San José-Enériz E; Agirre X; Sánchez-Arias JA; Vilas-Zornoza A; Ugarte A; de Miguel I; Miranda E; Garate L; Fraga M; Santamarina P; Fernandez Perez R; Ordoñez R; Sáez E; Roa S; García-Barchino MJ; Martínez-Climent JA; Liu Y; Wu W; Xu M; Prosper F; Oyarzabal J
    J Med Chem; 2018 Aug; 61(15):6518-6545. PubMed ID: 29953809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural basis for G9a-like protein lysine methyltransferase inhibition by BIX-01294.
    Chang Y; Zhang X; Horton JR; Upadhyay AK; Spannhoff A; Liu J; Snyder JP; Bedford MT; Cheng X
    Nat Struct Mol Biol; 2009 Mar; 16(3):312-7. PubMed ID: 19219047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimization of cellular activity of G9a inhibitors 7-aminoalkoxy-quinazolines.
    Liu F; Barsyte-Lovejoy D; Allali-Hassani A; He Y; Herold JM; Chen X; Yates CM; Frye SV; Brown PJ; Huang J; Vedadi M; Arrowsmith CH; Jin J
    J Med Chem; 2011 Sep; 54(17):6139-50. PubMed ID: 21780790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery, design and synthesis of 6H-anthra[1,9-cd]isoxazol-6-one scaffold as G9a inhibitor through a combination of shape-based virtual screening and structure-based molecular modification.
    Chen WL; Wang ZH; Feng TT; Li DD; Wang CH; Xu XL; Zhang XJ; You QD; Guo XK
    Bioorg Med Chem; 2016 Nov; 24(22):6102-6108. PubMed ID: 27720557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detailed Exploration around 4-Aminoquinolines Chemical Space to Navigate the Lysine Methyltransferase G9a and DNA Methyltransferase Biological Spaces.
    Rabal O; Sánchez-Arias JA; San José-Enériz E; Agirre X; de Miguel I; Garate L; Miranda E; Sáez E; Roa S; Martínez-Climent JA; Liu Y; Wu W; Xu M; Prosper F; Oyarzabal J
    J Med Chem; 2018 Aug; 61(15):6546-6573. PubMed ID: 29890830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.